Dyax

In 1997, Dyax licensed its Ladner Phage Display patents to CAT and CAT granted certain limited rights to Dyax in relation to its Phage Display technology patents.

In 2003, CAT and Dyax agreed to expand this access and to grant freedom to operate under each other's Phage Display technology patents. CAT granted Dyax worldwide licences for research purposes accessing all the Phage Display technology patents controlled by CAT and options for licences to develop therapeutic and diagnostic antibody products under CAT's patents. In return CAT will receive milestone and royalty payments on antibody products successfully developed by Dyax and its licensees. CAT also gained the option to co-fund and co-develop with Dyax, antibodies discovered by Dyax as well as the right to share in Dyax' revenues from certain other applications of Phage Display. In addition, CAT's obligation to pay royalties under the 1997 agreement to Dyax, for rights in respect of Dyax' Ladner patents on antibody therapeutics that CAT develops, was removed.

In January 2005, two monoclonal antibody drug candidates from Dyax' proprietary Phase Display libraries, IMC-11F8 and IMC-1121B, entered Phase I clinical trials at ImClone Systems, as a result of which CAT received a milestone payment.